Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens Meeting Abstract
| Authors: | Lu, J. M.; Kalinsky, K.; Tripathy, D.; Sledge, G. W.; Gradishar, W. J.; O'Regan, R.; O'Shaughnessy, J.; Modi, S.; Park, H.; McCartney, A.; Frentzas, S.; Shannon, C. M.; Eek, R. W.; Martin, M.; Curigliano, G.; Jerusalem, G. H. M.; Huang, C. S.; Press, M. F.; Tolaney, S. M.; Hurvitz, S. A. |
| Abstract Title: | Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680304771 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS1112 |
| Notes: | Meeting Abstract: TPS1112 -- Meeting also held virtually -- Source: Wos |
